<DOC>
	<DOC>NCT01300416</DOC>
	<brief_summary>This study will access the GI complaints on patients reported outcomes and to determine the improvement in quality of life in patients.</brief_summary>
	<brief_title>Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms</brief_title>
	<detailed_description />
	<criteria>Patient received kidney transplant at least 1 month prior to study with MMF as a part of the treatment for at least 2 weeks. Eligible to convert to myfortic because of GI complaints or not currently experiencing GI complaints and stable on current immunosuppressive regimen. At least 18 years of age; Willing to provide written informed consent; and Able to meet all study requirements including completing paper questionnaires and completing two study visits. GI symptoms assumed or known not be caused by MPA therapy and have recent acute rejection at least 1 week prior to the study. Breastfeeding or pregnant woman. Patients with psychiatric illness. Underlying acute medical intervention or hospitalization Receiving investigational drug within 30days prior to study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>mycophenolate sodium</keyword>
	<keyword>EC-MPS</keyword>
	<keyword>Health Related Quality of Life</keyword>
	<keyword>GI symptoms</keyword>
	<keyword>Immunosuppressants</keyword>
	<keyword>HRQL</keyword>
	<keyword>PGWB</keyword>
	<keyword>GIQLI</keyword>
</DOC>